Quarterly report · Q2
3937.TEDINET S100PJRL
Period2022-04-01 → 2022-09-30
Filed2022-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥4.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥502m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥436m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥495m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥478m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥495m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥466m | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥337m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥832m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥350m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥337m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥350m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥5.9bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥5.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥4.7bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.8bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥1.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.1bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥3.8bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.2bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.7bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.6bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥498m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥874m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥498m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥33m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥203m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥48m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥235m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥152m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥97m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥28.58 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥12.24 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥70.38 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.63 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.79 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥27.88 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥68.49 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥28.81 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 69.7% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.8% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.7% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥22m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥22m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥159m |
| jpcrp040300-q2r_E32408-000Globalreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E32408-000Globalreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E32408-000Globalreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥22m |
| jpcrp040300-q2r_E32408-000Globalreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥216m |
| jpcrp040300-q2r_E32408-000Medicalreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥756m |
| jpcrp040300-q2r_E32408-000Medicalreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥756m |
| jpcrp040300-q2r_E32408-000Medicalreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥444m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥22m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥660m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥22m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥660m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥45m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥45m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥162m |
| jpcrp040300-q2r_E32408-000Globalreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E32408-000Globalreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.5bn |
| jpcrp040300-q2r_E32408-000Globalreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥45m |
| jpcrp040300-q2r_E32408-000Globalreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥199m |
| jpcrp040300-q2r_E32408-000Medicalreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥740m |
| jpcrp040300-q2r_E32408-000Medicalreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥740m |
| jpcrp040300-q2r_E32408-000Medicalreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥399m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥2.3bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥2.3bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥45m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥598m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥2.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥2.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥45m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥598m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 495
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of intangible assets inv cf | Prior1YTDDuration | -11432000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -188000 | JPY |
| Other net inv cf | Prior1YTDDuration | -103000 | JPY |
| Other net inv cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -47935000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -33495000 | JPY |
| Increase in short term loans payable fin cf | Prior1YTDDuration | 100000000 | JPY |
| Increase in short term loans payable fin cf | CurrentYTDDuration | 100000000 | JPY |
| Decrease in short term loans payable fin cf | Prior1YTDDuration | -100000000 | JPY |
| Decrease in short term loans payable fin cf | CurrentYTDDuration | -100008000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | Prior1YTDDuration | 15440000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | CurrentYTDDuration | 12250000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -143000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -94771000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -29731000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -45814000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -82432000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -106473000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -96866000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -234818000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | -25148000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 57862000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 328183000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 287608000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 2773335000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 3342526000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 3101519000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 3630135000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 148445000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 158059000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 22078000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 23728000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 11261000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 6149000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | － | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | 74000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E32408-000GlobalReportableSegmentMember | 1528529000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E32408-000MedicalReportableSegmentMember | 740110000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 2268639000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2268639000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 2268639000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E32408-000GlobalReportableSegmentMember | 45111000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E32408-000MedicalReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 45111000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 45111000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -45111000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E32408-000GlobalReportableSegmentMember | 1573640000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E32408-000MedicalReportableSegmentMember | 740110000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |